StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Down 1.9 %
Shares of NASDAQ:PULM opened at $2.04 on Wednesday. The company has a 50-day moving average price of $1.87 and a 200-day moving average price of $1.88. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $3.14.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.57) EPS for the quarter. The firm had revenue of $2.20 million for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- ESG Stocks, What Investors Should Know
- 3 Stocks Leading the U.S. Agriculture Comeback
- Following Congress Stock Trades
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Energy and Oil Stocks Explained
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
